Search results for "BOS"

showing 10 items of 3713 documents

Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Inst…

2018

: Recommended strategy for venous thromboembolism (VTE) diagnosis includes the use of sensitive D-dimer (DDi) assays along with pretest probability (PTP) assessment. The Clinical and Laboratory Standards Institute (CLSI) recently issued a guideline (US FDA endorsed) on DDi in VTE exclusion. Such guideline specifies the ideal D-dimer assay characteristics and target population. Demonstrate STA-LiatestD-Di performance combined with a PTP score for proximal deep vein thrombosis (pDVT) exclusion in a CLSI compliant study. International, multicenter, prospective nonrandomized, noninterventional clinical outcome management study conducted in a standard-of-care setting. DDi was measured in DVT-sus…

AdultMalemedicine.medical_specialtyDeep veinShort Communications030204 cardiovascular system & hematologySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsSTA-Liatest DDi03 medical and health sciences0302 clinical medicineInternal medicineOutpatientsD-dimermedicineHumansProspective StudiesProspective cohort studyexclusiondeep venous thrombosisAgedVenous ThrombosisUnited States Food and Drug Administrationbusiness.industryImmunoturbidimetryHematologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseThrombosisUnited StatesPulmonary embolismClinical trialPre- and post-test probabilitymedicine.anatomical_structureD-dimerFemalebusiness030215 immunologyBlood Coagulation & Fibrinolysis
researchProduct

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

2007

In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the relapse rate and progression of disability. In patients with chronic progressive MS, a beneficial effect of IVIG was not documented in placebo controlled studies. This trial investigated the influence of IVIG in primary (PPMS) and secondary (SPMS) chronic progressive MS. Two-hundred and thirty-one patients stratified for PPMS ( n = 34) and SPMS ( n = 197) were randomly assigned to IVIG 0.4 g/kg per month or to placebo for 24 months. Primary endpoints were 1) the time to sustained progression of disease identified as worsening of the expanded disability status scale (EDSS) sustained for 3 months, and …

AdultMalemedicine.medical_specialtyDiseasePlaceboPlacebosCentral nervous system diseaseDisability EvaluationDegenerative diseaseQuality of lifeRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProspective StudiesDepression (differential diagnoses)AgedExpanded Disability Status Scalebusiness.industryMultiple sclerosisImmunoglobulins IntravenousMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseSurgeryTreatment OutcomeNeurologyDisease ProgressionFemaleNeurology (clinical)businessMultiple Sclerosis Journal
researchProduct

Investigation into isoprenaline resistance in patients with obstructive lung disease

1974

12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.

AdultMalemedicine.medical_specialtyDrug ResistanceDrug resistancePlaceboPlacebosElectrocardiographyHeart RateIsoprenalineInternal medicineHeart ratemedicineHumansPlethysmographInfusions ParenteralPharmacology (medical)Lung Diseases ObstructiveAgedPlethysmography Whole BodyAsthmaPharmacologyAnalysis of VarianceClinical Trials as Topicbusiness.industryAirway ResistanceIsoproterenolGeneral MedicineMiddle Agedmedicine.diseaseStimulation ChemicalObstructive lung diseaseAirway ObstructionBronchodilatationAnesthesiaInjections IntravenousCardiologyFemalebusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

2018

Background Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. Objective We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma (SEA). Methods COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859 ) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT01000506 ). Patients received 100 mg of subcutaneous mepolizumab every 4 weeks plus standard of care until a protocol-def…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsExacerbationInjections Subcutaneous[SDV]Life Sciences [q-bio]ImmunologyEosinophilic asthmaAntibodies Monoclonal HumanizedPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodSurveys and QuestionnairesInternal medicineEosinophiliamedicineHumansImmunology and AllergyIn patientAnti-Asthmatic Agents030212 general & internal medicineAdverse effectRespiratory Tract InfectionsComputingMilieux_MISCELLANEOUSAsthmabusiness.industryMiddle Agedmedicine.diseaseAsthma3. Good healthEosinophils[SDV] Life Sciences [q-bio]Treatment Outcome030228 respiratory systemAsthma Control QuestionnaireBronchitisFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct

Detection of spontaneous echocardiographic contrast within the left atrium by transesophageal echocardiography: spontaneous echocardiographic contrast

1986

Transesophageal echocardiography was performed in 314 patients over a period of 24 months using a 3.5 MHz phased-array system fitted to the distal end of a conventional 12 mm endoscope. In 12 patients (2.6%) transesophageal echocardiography could not be performed because of adverse reaction to the gastroscopic procedure. Side effects were a transient A-V block in one patient and asthmatic attack in another. Mitral valve lesions were found in 99 of 314 patients. In 9 of these 99 patients (11%), including 1 patient with mitral valve stenosis and sinus rhythm, 2 with atrial fibrillation, 3 with disc, and 3 with porcine mitral prosthesis, spontaneous echocardiographic contrast was found within …

AdultMalemedicine.medical_specialtyEndoscopeEsophagusPostoperative ComplicationsMitral valve stenosisInternal medicineMitral valveHumansMitral Valve StenosisMedicineSinus rhythmHeart AtriaEsophagusbusiness.industryMitral Valve InsufficiencyThrombosisAtrial fibrillationGeneral MedicineIntracranial Embolism and ThrombosisMiddle Agedmedicine.diseasePeripheralmedicine.anatomical_structureEmbolismEchocardiographyHeart Valve Prosthesiscardiovascular systemCardiologyFemaleRadiologyCardiology and Cardiovascular MedicinebusinessClinical Cardiology
researchProduct

Coronary artery stenosis treatment in aging patients with inherited Factor VII deficiency: Where do we stand?

2017

Aging with rare bleeding disorders such as factor VII (FVII) deficiency poses several challenges to treatment because of the occurrence of cerebral and cardiovascular age-related comorbidities and high bleeding risks. We report a case of long-term treatment with antiplatelet agents and contemporary prophylaxis of bleeding in a woman affected by severe FVII deficiency diagnosed with symptomatic coronary artery stenosis. Information on the management of antithrombotic treatment in rare bleeding disorders is lacking and mainly limited to anecdotal reports or side effects secondary to replacement therapy. We also briefly reviewed available data on the treatment of arterial thrombosis in FVII de…

AdultMalemedicine.medical_specialtyFactor VII DeficiencyCardiovascular risk factorsCoronary stenosis030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundAntithrombotic treatment0302 clinical medicineInternal medicinemedicineHumanscardiovascular diseasesFactor VII deficiencyChildAgedFactor VIIbusiness.industryCoronary StenosisHematologyMiddle Agedmedicine.diseaseThrombosischemistryCardiologyFemalebusiness030215 immunologyTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins.

2006

The aim of this study was to evaluate different durations of treatment in patients with calf venous thrombosis (CVT) involving 1 or more deep veins. The authors studied 2 groups of patients with postsurgical CVT diagnosed by echo-color Doppler. The first group consisted of 68 patients with CVT involving a single vein, and the second group consisted of 124 patients with CVT involving 2 or more veins. Immediately after diagnosis, all patients were treated with nadroparin calcium and sodium warfarin. Heparin treatment was withdrawn after 5–6 days of treatment, when the international normalized ratio (INR) was stabilized between 2 and 3. Each group was divided into 2 subgroups receiving antico…

AdultMalemedicine.medical_specialtyFemoral vein030204 cardiovascular system & hematologyDrug Administration ScheduleLesion03 medical and health sciences0302 clinical medicinePostoperative ComplicationsMedicineHumans030212 general & internal medicineThrombusUltrasonography Doppler ColorVeinAgedVenous ThrombosisLegbusiness.industryAnticoagulantsNadroparinHeparinMiddle Agedmedicine.diseaseNadroparin calciumSurgeryVenous thrombosismedicine.anatomical_structureAnesthesiacardiovascular systemFemaleWarfarinmedicine.symptomCardiology and Cardiovascular MedicinebusinessSurgical patientsmedicine.drugAngiology
researchProduct

Sex-related differences in D-dimer levels for venous thromboembolism screening.

2021

Background D-dimer is generally considered positive above 0.5 mg/L irrespective of sex. However, women have been shown to be more likely to have a positive D-dimer after controlling for other factors. Thus, differences may exist between males and females for using D-dimer as a marker of venous thromboembolic (VTE) disease. We hypothesized that the accuracy of D-dimer tests may be enhanced by using appropriate cutoff values that reflect sex-related differences in D-dimer levels. Methods This research is a secondary analysis of a multicenter, international, prospective, observational study of adult (18+ years) patients suspected of VTE, with low-to-intermediate pretest probability based on We…

AdultMalemedicine.medical_specialtyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineInternal medicineD-dimermedicineHumansProspective StudiesVenous ThrombosisReceiver operating characteristicbusiness.industry030208 emergency & critical care medicineGeneral MedicineVenous Thromboembolismmedicine.diseaseConfidence intervalPulmonary embolismPre- and post-test probabilityDeep vein thrombosis (DVT)CohortEmergency MedicineFemalebusinessPulmonary EmbolismLower limbs venous ultrasonographyAcademic emergency medicine : official journal of the Society for Academic Emergency MedicineREFERENCES
researchProduct

Effect of manual therapy versus proprioceptive neuromuscular facilitation in dynamic balance, mobility and flexibility in field hockey players. A ran…

2018

To compare the effectiveness of a specific Manual Therapy (MT) protocol applied to field hockey players (FHP), versus a Proprioceptive Neuromuscular Facilitation (PNF) protocol, in the improvement of dynamic balance, active range of movement and lumbar flexibility one-week and four-weeks after the treatment.Randomized controlled trial. Participants were assigned to 2 groups: MT and PNF. 30 min' sessions were performed once a week for three weeks. Three evaluations were performed: basal, one-week and four-weeks post-treatment.University of Valencia (Spain).22 in MT group and 20 in PNF group.Dynamic Balance, measured with Star Excursion Balance Test; Active Range of Motion (ROM), using a manu…

AdultMalemedicine.medical_specialtyFlexibility (anatomy)Field hockeyAdolescentPhysical Therapy Sports Therapy and Rehabilitationlaw.invention03 medical and health sciencesYoung Adult0302 clinical medicinePhysical medicine and rehabilitationRandomized controlled triallawMuscle Stretching ExercisesmedicineHumansOrthopedics and Sports MedicineKneeRange of Motion ArticularDynamic balancePostural Balance030222 orthopedicsHipProprioceptionArthrometry Articularbusiness.industryLumbosacral Region030229 sport sciencesGeneral MedicineProprioceptionMusculoskeletal ManipulationsBiomechanical Phenomenamedicine.anatomical_structureHockeyAthletesAthletic InjuriesFemaleManual therapyAnkleAnklebusinessRange of motionPhysical therapy in sport : official journal of the Association of Chartered Physiotherapists in Sports Medicine
researchProduct

Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer

2012

Cancer-related disseminated intravascular coagulation (DIC) is a life-threatening condition for which no effective treatment is currently available. Protein C (PC), a modulator of coagulation as well as the inflammatory system, has been successfully tested (in its activated recombinant form [a-rPC]) in sepsis-related coagulopathy, but with an increased risk for major bleeding. Plasma-derived PC (pd-PC) is more suitable than a-rPC in patients at high risk from bleeding due to its self-limiting process. We carried out a single-arm study evaluating the role of pd-PC in adult cancer patients with overt DIC. Over a period of 3 years, we treated 19 patients with overt DIC and a PC plasma concentr…

AdultMalemedicine.medical_specialtyGastroenterologySettore MED/15 - Malattie Del SangueNeoplasmsInternal medicineCoagulopathymedicineHumansBlood Coagulationdisseminated intravascular coagulationSurvival analysisAgedAged 80 and overDisseminated intravascular coagulationHematologic Testsbusiness.industryPlasma derivedAnticoagulantsCancerHematologyMiddle Agedmedicine.diseaseSurvival AnalysisThrombosisSurgeryCoagulationFemalebusinessProtein CProtein Cmedicine.drugAmerican Journal of Hematology
researchProduct